Bacterial Enzymes as Targets for Drug Discovery

Part I Primer of antibiotic discovery process<br>1. Antibacterial drug discovery: A Silent Pandemic<br>2. Current scenario and future prospective of drug discovery and development against bacterial enzymes<br>3. Clinical diagnostics of bacterial infections and their resistance to Antibiotics — Current State and Novel Enabling Technologies Implementation Perspectives<br>4. An Odyssey into Phylogenetic Functional Conservation of Novel Antibacterial Targets in Human Pathogens<br>5. Validation of drug targets using molecular methodologies and enzymatic activity assays for validation of inhibitory potential<br>6. Computational tools to identify potential drug targets in bacteria<br>7. Antimicrobial drug resistance and bypassing strategies<br>Part II Bacterial enzyme as drug targets<br>8. Designing Tomorrow's Antibiotics: Cutting-Edge Strategies and Technologies<br>9. Inhibiting the replication by targeting topoisomerases<br>10. Role of beta lactamases in antibiotic drug discovery<br>11. Selective vs broad spectrum inhibition of novel outer membrane targets in Gram negatives<br>12. Ribosomal binding antibacterial agents<br>13. RNA polymerase: A key target for Novel Antimicrobial Therapeutic Strategies<br>14. Colistin resistance and strategies against superbug, where we are?<br>15. Deoxythymidine pathway enzymes as an antibacterial target<br>16. Arresting the peptidoglycan synthesis to kill the bacteria<br>17. Clp protease complex as a therapeutic target for tuberculosis<br>18. PlaF: a bacterial Lands cycle phospholipase A mediating membrane phospholipid degradation and virulence adaptation<br>19. Bacterial TIR domain-containing proteins as drug targets<br>20. Drug Repurposing: Tackling the antibiotic resistance with existing therapeutics